Close
Close
Treatment Database
peptide-drug conjugate combining [(Tyr3,Cys8) octreotate amide] and N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl) maytansine
Trade Name not avaiable
Orphan Indication Neuroendocrine tumors
USA Market Approval
USA Designation Date 20-11-2018
Sponsor Tarveda Therapeutics, Inc.
134 Coolidge Avenue
Watertown, Massachusetts, 02472
More about Neuroendocrine Tumors
Free Newsletter
Related Videos